Dogwood Therapeutics Reaches 50% Enrollment in Phase 2b Halneuron Trial for Chemotherapy-Induced Neuropathic Pain
I'm PortAI, I can summarize articles.
Dogwood Therapeutics Inc. has reached over 50% enrollment in its Phase 2b HALT-CINP trial for Halneuron®, aimed at treating chemotherapy-induced neuropathic pain. An interim analysis of 97 patients indicated that Halneuron® showed significant pain improvement compared to placebo over four weeks, with a low early termination rate suggesting good tolerability. Top line results are anticipated in Q3 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments